BA
Brenton Karl Ahrens
Director

Brenton Karl Ahrens insider trades: Iterum Therapeutics (ITRM) stock buys and sales

Director, Iterum Therapeutics Last trade Sep 20, 2022 24 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2011
4
Companies
last trade 2022

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Brenton reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Sep 20, 2022ITRM↓ Sell$68K
Sep 15, 2022ITRM↓ Sell$94K
Sep 12, 2022ITRM↓ Sell$77K
May 30, 2018ITRM↑ Buy$6.6M
Jul 24, 2012DRTX↑ Buy$5.0M
Mar 5, 2012ACTV↓ Sell$3.1M
Mar 1, 2012ACTV↓ Sell$2.2M
Feb 28, 2012ACTV↓ Sell$2.2M
May 31, 2011ACTV↓ Sell$20.6M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ITRM insiders

Open-market trades in the last 12 months

About Brenton Karl Ahrens's insider trades

Brenton Karl Ahrens is a director at Iterum Therapeutics (ITRM). Since May 31, 2011, Brenton has reported 2 open-market purchases worth $11.6M and 7 sales worth $28.4M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (13 filings), conversions (3 filings), option exercises (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ITRM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.